apy System (Gaymar, Orchard Park, NY). A midline scalp incision from 5 mm anterior to bregma to 5 mm posterior to lambda exposed the skull. Two stainless steel anchor screws were secured to the skull. The skull was opened at -4.84 mm relative to bregma and 0.65 mm lateral to midline for access to the pontine reticular nucleus, oral part (PnO) according to the mouse brain atlas. 30 A 26-gauge stainless steel microinjection guide tube was stereotaxically positioned to permit subsequent PnO microinjection aimed for 5.0 mm ventral to bregma. The guide tube was cemented in place with dental acrylic and occluded with a stainless steel stylet. Two additional holes were made in the skull for implanting cortical EEG electrodes. One electrode was placed above motor cortex (M1/M2) and the second electrode was positioned above the hippocampus. 30 The electrodes were gathered into a plastic connector (Plastics One, Roanoke, VA) and encased in dental cement. Mice were allowed to recover for several days before initiating the microinjection experiments. Animals were housed individually and in constant illumination.
Microinjection procedure
Neostigmine bromide (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile saline (0.9%) immediately prior to use. Microinjections were performed between 08:00 and 16:30 hrs. A manual microdrive was used to deliver saline (50 nl) or neostigmine (0.133 µg/50 nl; 8.8 mM) during a 1 minute interval. The injector remained in the brain for an additional 1 minute post-injection before it was replaced by the stainless steel stylet. The sleep, locomotor, or breathing studies then were started. All measures of drug effects were limited to 2 hours post-injection.
Sleep recordings
Mice were adapted to a BAS Raturn ® system (Bioanalytical Systems, Inc., West Lafayette, IN) where they had free access to food, water, and nesting material. The cable system electrically monitored mouse movement and generated a counter movement of the Plexiglas enclosure. This prevented cable twisting and build up of cable resistance over time. All animals displayed normal feeding, grooming, and locomotor activity in the Raturn ® environment. States of sleep and wakefulness were recorded within 5 minutes following PnO microinjection. The EEG recordings were obtained in analog format using a Grass Instruments (West Warwick, RI) Model 7 polygraph and digitized with a Grass Model 15RXi digital polygraph and Polyview ® software.
Locomotor recordings
Free ranging locomotor activity was quantified using real-time video recordings of mice. Within 5 minutes after PnO microinjection, the mice were placed in an open field grid (length = 67 cm x width = 56 cm x depth = 19 cm). The implanted head cap was not attached to a cable, and each mouse was free to explore the grid. The floor of the grid was registered as video pixels and every pixel crossing was digitized and summed. These digital video recordings provided a quantitative index of locomotion and movements such as grooming behavior.
Respiratory recordings
The effects of PnO microinjection on breathing were quantified using a Buxco (Sharon, CT) plethysmograph for unrestrained mouse (PLY3211) and BioSystem XA software ® . Mice were placed in the calibrated whole-body plethysmograph after PnO microinjections, and breathing was measured for 20 minutes.
Data analysis
Signals from the cortical EEG electrodes were amplified and digitized with a sampling rate of 128 Hz. The EEG was analyzed by Fast Fourier Transformation (FFT) in two-second bins. Analyses were conducted in 0.5-Hz increments for frequencies ranging from 0.5 Hz to 25 Hz. The bins were averaged over 1-minute intervals of EEG recordings. The total power (Vrms) for each frequency interval of cortical EEG was quantified as power spectral density.
Plethysmographic breathing data were used to quantify respiratory frequency, tidal volume, and minute ventilation. Additional measures of respiratory cycle timing included inspiratory time (Ti), expiratory time (Te), total respiratory cycle time (Ttot=Te+Ti), inspiratory flow (VT/Ti), and an index of respiratory effort (Ti/Ttot). Data are reported as mean ± standard deviation (SD). Differences in these respiratory measures between saline and neostigmine treatment conditions were evaluated by t-test. A probability (p) value of < 0.05 was used to indicate a significant difference.
Histological analysis of microinjection sites
Upon completion of all experiments, mice were decapitated and brains were removed, frozen, and sectioned coronally at 40 microns in thickness. Brain stem sections were collected serially, mounted on glass slides, fixed in hot (80°C) paraformaldehyde vapors, and stained with cresyl violet. Microinjection sites were localized by comparing each section containing a microinjector-induced lesion to the mouse brain atlas. 30 Figure 1 illustrates a representative microinjection site in the PnO. The coronal brainstem schematic 30 indicates that all microinjections were made into the PnO. The average (mean±SD) location of all microinjection sites was 4.64±0.18 mm posterior to bregma, 0.81±0. mm lateral to bregma, and 4.69±0.37 mm ventral to the surface of the skull. Continuous behavioral observations and EEG recordings were made for 2 hours after injection. Following saline microinjections, wakefulness was characterized by normal grooming and exploratory behavior. During sleep intervals following saline microinjection, animals assumed normal sleep postures, and twitching of the vibrissae was observed during REM sleep. Sleep intervals were periodic and interrupted by bouts of wakefulness. Typical EEG recordings obtained from freely moving mouse across the sleep/wake cycle are shown in Figure 2 . During wakefulness ( Figure 2A ) and REM sleep ( Figure 2C ) the EEG was characterized by low-voltage waves that increased in amplitude and slowed in frequency during non-REM (NREM) sleep ( Figure 2B ). The EEG recordings during REM sleep ( Figure 2C ) also revealed a typical theta rhythm.
RESULTS
Microinjection of neostigmine produced a REM sleep-like state. Similar to natural REM sleep, mice were immobile after neostigmine administration. As has been shown for cat, 19 the latency to onset for the loss of motor activity was less than 5 minutes after neostigmine administration, and this immobility lasted for up to 60 minutes after the injection ( Figure 3 ). During the cholinergically induced REM sleep-like state, breathing was observed to be irregular, as has been reported for cat. 31 The EEG following neostigmine injection ( Figure 2D ) was characterized by low-amplitude waves, similar to the EEG of REM sleep ( Figure 2C ) and wakefulness ( Figure 2A ). Figure 4 illustrates the spectral EEG profiles characteristic of wakefulness, NREM sleep, REM sleep, and the neostigmine-induced REM sleep-like state. Figure 4A shows the increase in delta power (0.5 Hz to 4 Hz) during NREM sleep relative to wakefulness and REM sleep. The peak in the REM sleep function shows the 6 Hz to 9 Hz theta activity that is a defining characteristic of REM sleep. 32 Figure 4B reveals that microinjection of saline did not alter the spectral profile of the EEG across the sleep/wake cycle compared to no microinjection ( Figure 4A ). Figure 4C shows the power spectral density of EEG recorded after PnO neostigmine administration.
Respiratory recordings following pontine microinjections were obtained from 4 mice. Representative traces of breathing recorded from unrestrained mice in the plethysmograph are shown in Figure 5 . Analyses of thousands of individual breaths were averaged to create the means, comprised of 11 time intervals, each 5 minutes in duration. Thus, the comparisons summarized by Figure 6 are based on 11 measurement intervals following saline injection and 11 measurement intervals following neostigmine injection. This averaging technique was used to avoid the inflated degrees of freedom known to be associated with very large sample sizes. Respiratory rate ( Figure 6A ) as breaths per minute (mean±SD) following saline was 360.6±88. Pontine microinjection of neostigmine caused a significant (p<0.0001) decrease in rate of breathing (128.7±33.6). Tidal volume ( Figure 6B ) averaged 0.21±0.09 mL following saline administration, and following neostigmine tidal volume (0.15±0.02) was not significantly decreased. Minute ventilation ( Figure  6C ) was significantly decreased (p<0.0002) from 77.2±41.7 mL/min after saline to 19.3±4.1 mL/min following neostigmine administration. The neostigmine-induced slowing of respiratory rate ( Figure 5 ) is shown quantitatively in Figures 6D, E , and F. Pontine neostigmine significantly increased (p<0.0001) total respiratory cycle time (Ttot) by increasing both the duration of inspiration (Ti) and expiration (Te). The inspiratory phase of the respiratory cycle increased in duration from 0.064±0.01 seconds after saline to 0.152±0.02 seconds after neostigmine ( Figure  6D ). The expiratory phase was increased from an average duration after saline of 0.15±0.07 seconds to 0.36±0.12 seconds following neostigmine ( Figure 6E ). Thus, total respiratory cycle duration (Ttot) was increased ( Figure 6F ) from 0.22±0.07 seconds after saline to 0.51±0.12 seconds by microinjection of neostigmine. Figure 7 plots the average ratio of Ti/Ttot and VT/Ti for saline and neostigmine microinjection conditions. The Ti/Ttot ratio provides an estimate of respiratory drive and Figure 7A shows that there was no significant effect of neostigmine on Ti/Ttot ratio. Inspiratory flow per unit time (mL/s) can be expressed as the VT/Ti ratio. Neostigmine caused a significant decrease (p<0.0001) in VT/Ti ratio ( Figure 7B ). Inspiratory airflow following saline microinjection averaged 3.2±1.2 mL/s and this decreased to 1.0±0.19 mL/s following neostigmine administration. x reduced locomotor activity, and depressed breathing. Respiratory depression was manifest as a decrease in respiratory rate, a decrease in minute ventilation, and an increase in respiratory cycle timing. These data from intact, unanesthetized mouse are discussed relative to homologous data from intact, unanesthetized rat and cat. Interested readers are referred elsewhere for a review including use of the cholinergic model in surgically reduced and anesthetized animals. 33 Limitations and unanswered questions are addressed throughout the discussion. Early site-localization studies in cat made clear that similarities and differences between REM sleep and the cholinergically evoked REM sleep-like state were dependent, in part, on injection site within the pons. 34 Microinjection studies in rat identified the caudal portion of the PnO as the most efficacious region for cholinergic REM sleep enhancement. 27 The pontine microinjection sites summarized by Figure 1 provide only an initial perspective on pontine regions in B6 mouse from which cholinergic REM sleep enhancement can be produced. These sites all were localized in the PnO. This part of the mouse PnO is homologous to the region in rat (PnO) and cat (medial pontine reticular formation) where cholinomimetics enhance REM sleep. 22 The results encourage future studies aiming to map the extent of pontine regions in B6 mouse from which REM sleep can be enhanced by cholinomimetics.
DISCUSSION

Pontine Neostigmine Enhances REM Sleep
The EEG is an important tool for assessing cortical and behavioral arousal. The only objective measure of human sleep need is the multiple sleep latency test, which uses EEG documentation of sleep onset. 35 Sleep need in mouse is under genetic control, 36 and gene expression changes with arousal state. 37 Analysis of quantitative trait loci suggest a surprisingly small number of candidate genes modulating sleep. 38, 39 Genomic data reinforce enthusiasm for efforts to understand how mouse sleep varies as a function of strain, 36 integral proteins, 40 and cell surface receptors. 41, 42 In mouse, sleep need is reflected by EEG delta power. 36 The EEG recordings across the sleep cycle in the present study ( Figure  2 ) are similar to those reported previously for B6 mouse. 32 Pontine administration of neostigmine caused EEG activation ( Figure 2 ) that was reflected in the FFT analyses (Figure 4 ). Previous studies of intact, unanesthetized cat used FFT analyses to demonstrate similarities in EEG power during REM sleep and the REM sleep-like state caused by pontine carbachol injection. 43 In rat, microinjection of a cholinergic agonist into pontine regions homologous to mouse PnO (Figure 1 ) caused hippocampal theta characteristic of REM sleep. 44 Future studies in mouse will be able to determine the extent to which cholinomimetics increase hippocampal theta activity.
The present finding of REM sleep enhancement by neostigmine microinjection is limited to a single drug concentration. The results encourage future studies in B6 mouse, characterizing the concentration response curve and antagonist blocking of REM sleep enhancement by neostigmine. 19 Such studies will form the basis for species-specific com- parisons and for evaluating whether cholinergic REM sleep enhancement varies as a phenotype across mouse strains. Antagonist blocking studies also will be key for determining whether cholinergic REM sleep enhancement occurs via muscarinic cholinergic receptors as in rat and cat (reviewed in 22 ).
Microinjection of
Locomotion was Inhibited by Pontine Neostigmine
Intracellular recordings from cat spinal alpha motoneurons revealed that the atonia of REM sleep is mediated by descending inhibitory postsynaptic potentials (IPSPs). 45 Pontine administration of the cholinergic agonist carbachol into feline PRF produces spinal IPSPs that are indistinguishable from the IPSPs of spontaneous REM sleep. 46 The present finding that pontine administration of neostigmine significantly inhibited locomotion (Figure 3 ) is consistent with a large body of evidence that the pons contributes to REM sleep-dependent motor atonia. 47, 48 Figure 3 results suggest that application of the cholinergic model to mouse also may provide a powerful tool for mechanistic studies of sleep-related motor dysfunction. Experimentally induced mutations in mice have identified genes causing locomotor ataxia. 49 Many sleep disorders involve failure to suppress or to initiate specific movements. 47 Sleep is a heritable phenotype, 32, 36, 38, 39 thus it is reasonable to anticipate a genetic basis for some sleep-related disorders of motor control.
Pontine Neostigmine Causes Sleep Disordered Breathing
Ventilation and responsiveness to hypercapnic challenge vary significantly as a function of mouse strain. 50 There are now compelling data demonstrating that breathing is a genetically modulated phenotype. 51, 52 Previous studies from intact, sleeping cat show that upper airway muscle electromyogram (EMG) and breathing are depressed by alterations in cholinergic neurotransmission within the pontine reticular formation (reviewed in 18, 53 ). The finding that pontine administration of neostigmine caused a REM sleep-like state in B6 mice (Figures 1-4) encouraged measurement of breathing following neostigmine administration. Compared to saline (control), breathing during the REM sleep-like state was characterized by decreased rate, prolonged pauses in breathing, and periodic patterns ( Figure 5 ). Periodic breathing is a feature of obstructive 54 and central 55 sleep apnea and has been postulated to reflect instability 56 of the respiratory pattern generator. Periodic breathing patterns have been described in B6 mouse. 57 Respiratory pauses homologous to apneas have been operationally defined in rat. 58, 59 The observations of respiratory pauses ( Figure 5C ) and periodic breathing ( Figure 5D ) during neostigmine-induced REM sleep demonstrate causal modulation by pontine cholinergic neurotransmission.
Neostigmine-induced alterations in breathing of B6 mice ( Figures 5-7) closely parallel the changes in breathing caused by administering cholinomimetics into homologous pontine regions of intact, unanesthetized cat. 31, 60 In cat, pontine cholinomimetics significantly reduced minute ventilation below waking levels by decreasing both respiratory rate and tidal volume. 31 The present data show that in mouse the neostigmine-induced decrease in minute ventilation occurred primarily as a function of a decrease in respiratory rate rather than tidal volume ( A. There was no difference between saline and neostigmine conditions for measures of the ratio of active inspiration to total respiratory cycle time (Ti/Ttot). B. In contrast, inspiratory flow (VT/Ti) was significantly decreased during the REM sleep-like state caused by neostigmine. Asterisk indicates a significant decrease relative to control (saline). Fig. 5A and 5B indicates that the decrease in inspiratory flow was a function of the large increase in respiratory cycle duration.
ures 6A-C). The significant slowing of breathing that occurred in mouse was due to increases in the duration of both inspiration and expiration ( Figures 6D-F) , and similar changes in respiratory cycle timing of cat also have been shown to be caused by pontine cholinomimetics. 31 The present data encourage comparisons of respiratory measures during REM sleep caused by neostigmine administration with respiratory measures during spontaneous REM sleep. Such data will provide insights into the similarities and differences in the mouse between natural REM sleep and the cholinergic model with respect to breathing. Inferences regarding the central drive to breathe can be made from the ratio of inspiratory time to total respiratory cycle time (Ti/Ttot) and from the ratio of tidal volume to inspiratory time (VT/Ti). In mouse, neostigmine significantly decreased VT/Ti and did not significantly alter Ti/Ttot (Figure 7 ). The present data cannot explain the mechanisms underlying these differences. The results do suggest future studies aiming to determine the degree to which the significant decrease in VT/Ti reflects cholinergically induced hypotonia of diaphragmatic pump muscles verses cholinergic dampening of central respiratory drive.
The finding that sleep-dependent respiratory depression can be caused by cholinergic agonists such as carbachol 31, 60 and bethanechol 61 and by the acetylcholinesterase inhibitor neostigmine (Figures 5-7) implies a causal role for the endogenous neurotransmitter acetylcholine (ACh). Direct measures of ACh in medial pontine reticular formation of cat support this view. 62, 63 Recent data indicate that ACh 64 and muscarinic cholinergic receptors 65 are present in the homologous PnO region of mouse.
Summary and Conclusions
The original demonstration that the cholinergic model of REM sleep could provide a productive tool for studying sleep-dependent changes in respiration 31, 60 has been supported by data from many laboratories (reviewed in 17, 18, 33 ) . Conscious rodent models of cardiopulmonary control during sleep have successfully demonstrated sleep-dependent alterations in blood pressure 66 and that repeated exposure to hypoxia significantly alters sleep. 67, 68 Hypoxia also has been shown to disrupt performance and neural substrates for learning 69 and to significantly alter brainstem transcription factors. 70 To our knowledge, the present results provide the first report of cholinergic REM sleep enhancement causing respiratory depression in mouse. The finding that pontine neostigmine enhances REM sleep and causes sleep disordered breathing is consistent with the conclusion that endogenous pontine ACh modulates sleep and breathing in B6 mouse. These initial results encourage future studies identifying similarities and differences in cholinergic REM sleep enhancement among inbred mice and in transgenic and knockout animals. Such comparisons will help characterize sleep and breathing as intermediate phenotypes that are determined, in part, by the lower-level phenotype of pontine cholinergic neurotransmission.
